Antibody In-Vitro In-Vivo RNA 
Drug Discovery World
MARCH 26, 2024
For example, progress made in developing gene mutant-specific inhibitors, antibody-drug conjugates (ADC), or cellular therapies. We were excited to unveil data showing that two distinct chemical series exhibit METTL1 inhibition in vitro at low nanomolar concentrations with minimal interference with other RNA and protein methyltransferases.
pharmaphorum
JANUARY 17, 2023
The intracellular barriers include endosomal escape, RNA sensors, and endonucleases. Conjugation of targeting ligands such as GalNAc, transferrin receptor antibodies, and lipophilic moieties to siRNAs and ASO have facilitated delivery to liver, muscle, and CNS tissues, respectively, in preclinical or clinical studies.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drug Discovery World
AUGUST 3, 2022
Oligonucleotides act on the RNA level through different molecular pathways, but there is a major drawback when using them as drugs: their poor bioavailability and cellular uptake. This is a common reaction within peptide chemistry and it has been approved by regulatory authorities for various antibody-drug conjugates 4. Anti-miRNA.
XTalks
APRIL 22, 2022
Both the areas of drug development and clinical trials are increasingly using in vitro assays to help determine the efficacy of an investigational therapeutic. The antibodies are conjugated to fluorochromes for them to be detected. What is Flow Cytometry?
Drug Discovery World
APRIL 12, 2023
Existing in vivo and in vitro models aren’t up to the challenge Preclinical tools exist for the evaluation and screening of potential drug candidates. Existing in vivo and in vitro models aren’t up to the challenge Preclinical tools exist for the evaluation and screening of potential drug candidates.
Drug Discovery World
JANUARY 20, 2023
Existing in vivo and in vitro models aren’t up to the challenge Preclinical tools exist for the evaluation and screening of potential drug candidates. Existing in vivo and in vitro models aren’t up to the challenge Preclinical tools exist for the evaluation and screening of potential drug candidates.
Expert insights. Personalized for you.
64 
Let's personalize your content